Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: A meta-analysis

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 680-691

  Liu, Yuqi ^a   Gao, Lei ^a   Song, Yanqiu ^b   Chen, Lian ^a   Xue, Qiao ^a   Tian, Jinwen ^a   Wang, Yu ^a   Chen, Yundai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Tianjin Chest Hospital   (China)

Author keywords

Diabetes mellitus; Eluting stent; Meta analysis; Percutaneous coronary intervention

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SAFETY; SIROLIMUS ELUTING CORONARY STENT; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; UNSTABLE ANGINA PECTORIS; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); CORONARY BLOOD VESSEL; DRUG ELUTING STENT; PATHOLOGY; PROCEDURES; PROSTHESIS; TREATMENT OUTCOME;

PACLITAXEL;

CLINICAL TRIALS AS TOPIC; CORONARY VESSELS; DIABETES MELLITUS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 84933528828     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.002     Document Type: Article

References (53)

1. A. Abizaid, R. Kornowski, G.S. Mintz, et al., The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation, J. Am. Coll. Cardiol. 32 (1998) 584-589.
2. A.J. Scheen, F. Warzee, V.M. Legrand, Drug-eluting stents: meta-analysis in diabetic patients, Eur. Heart J. 25 (2004) 2167-2189.
3. A.J. Scheen, F. Warzee, Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries, Diabetes Care 27 (2004) 1840-1841.
4. E. Mahmud, G. Bromberg-Marin, V. Palakodeti, et al., Clinical efficacy of drug-eluting stents in diabetic patients: A meta-analysis, J. Am. Coll. Cardiol. 51 (2008) 2385-2395.
5. G. Patti, A. Nusca, G. Di Sciascio, Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus, Am. J. Cardiol. 102 (2008) 1328-1334.
6. D.J. Kumbhani, A.A. Bavry, A.R. Kamdar, et al., The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials, Am. Heart J. 155 (2008) 640-647.
7. J.W. Moses, M.B. Leon, J.J. Popma, et al., Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery, N. Engl. J. Med. 349 (2003) 1315-1323.
8. G.W. Stone, S.G. Ellis, D.A. Cox, et al., A polymer-based paclitaxel-eluting stent in patients with coronary artery disease, N. Engl. J. Med. 350 (2004) 221-231.
9. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser, et al., Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents, J. Am. Coll. Cardiol. 48 (2006) 2584-2591.
10. J. Daemen, P. Wenaweser, K. Tsuchida, et al., Early and late stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study, Lancet 369 (2007) 667-678.
11. G.W. Stone, J.W. Moses, S.G. Ellis, et al., Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents, N. Engl. J. Med. 356 (2007) 998-1008.
12. R. DerSimonian, N. Laird, Meta-analysis in clinical trials, Control. Clin. Trials 7 (1986) 177-188.
13. Immunosuppreßion: 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003, HHS/HRSA/OSP/DOT and UNOS, Ann Arbor, MI, 2004.
14. Karen A. Hicks, H.M. James Hung, Kenneth W. Mahaffey, Roxana Mehran, Steven E. Nißen, Norman L. Stockbridge, Shari L. Targum, Robert Temple, Standardized Definitions for End Point Events in Cardiovascular Trials, October 20 2010.
15. I. Iakovou, T. Schmidt, E. Bonizzoni, et al., Incidence, predictors, and outcome of thrombosis after succeßful implantation of drug-eluting stents, JAMA 293 (2005) 2126-2130.
16. D.W. Park, S.W. Park, K.H. Park, et al., Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up, Am. J. Cardiol. 98 (2006) 352-356.
17. J.P. Higgins, S.G. Thompson, J.J. Deeks, et al., Measuring inconsistency in metaanalyses, BMJ 327 (2003) 557-560.
18. M. Egger, G. Davey Smith, M. Schneider, et al., Bias in meta-analysis detected by a simple, graphical test, BMJ 315 (1997) 629-634.
19. S.W. Lee, S.W. Park, Y.H. Kim, et al., A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial, J. Am. Coll. Cardiol. 53 (9) (2009) 812-813.
20. S.W. Lee, S.W. Park, Y.H. Kim, et al., A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetesmellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial, JACC Cardiovasc. Interv. 4 (3) (2011) 310-316.
21. S.W. Lee, S.W. Park, Y.H. Kim, et al., A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus, J. Am. Coll. Cardiol. 52 (9) (2008) 727-733.
22. A.J. Kirtane, R. Patel, C. O'Shaughneßy, et al., Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- And paclitaxel-eluting stents in patients with coronary artery disease, JACC Cardiovasc. Interv. 2 (10) (2009) 967-976.
23. E. Kedhi, M.E. Gomes, B. Lagerqvist, et al., Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: Insights from a nationwide coronary intervention register, JACC Cardiovasc. Interv. 5 (11) (2012) 1141-1149.
24. J. Cosgrave, P. Agostoni, L. Ge, et al., Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions, Am. J. Cardiol. 96 (12) (2005) 1663-1668.
25. M. Balducelli, P. Ortolani, P. Marzaroli, et al., Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry, Catheter. Cardiovasc. Interv. 75 (3) (2010) 327-334.
26. Y.J. Yang, B. Xu, S. Kang, et al., Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease, Chin. Med. J. (Engl.) 120 (21) (2007) 1868-1873.
27. A.T. Ong, J. Aoki, C.A. van Mieghem, et al., Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and TSEARCH registries), Am. J. Cardiol. 96 (3) (2005) 358-362.
28. J.S. Kim, B.H. Lee, Y.G. Ko, D. Choi, Y. Jang, P.K.Min, Y.W. Yoon, B.K. Hong, H.M. Kwon, M.S. Ahn, S.H. Lee, J.H. Yoon, B.K. Lee, B.O. Kim, B.K. Kim, S.J. Oh, D.W. Jeon, J.Y. Yang, J.R. Cho, J.H. Jung, S.K. Ryu, Korean Multicenter Angioplasty Team (KOMATE) Investigators, Comparison of Sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean Multicenter Angioplasty Team (KOMATE) registry, Catheter. Cardiovasc. Interv. 72 (5) (2008) 601-607.
29. M. Maeng, L.O. Jensen, A.M. Galloe, et al., Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: The diabetes and drug-eluting stent (DiabeDES) randomized angiography trial, Am. J. Cardiol. 103 (3) (2009) 345-349.
30. S.J. Jang, D.W. Park, W.J. Kim, et al., Differential long-term outcomes of zotarolimuseluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: Two-year subgroup analysis of the ZEST randomized trial, Catheter. Cardiovasc. Interv. 81 (7) (2013) 1106-1114.
31. T. Stiermaier, A. Heinz, D. Schloma, et al., Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetesmellitus (LIPSIA Yukon trial), Catheter. Cardiovasc. Interv. 83 (3) (2014) 418-424.
32. C. Simsek, L. Räber, M. Magro, et al., Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxeleluting stents in diabetic patients: The Bern-Rotterdam diabetes cohort study, Int. J. Cardiol. 170 (1) (2013) 36-42.
33. C. Briguori, F. Airoldi, G. Visconti, et al., Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: A randomized comparison of 3 drug-eluting stents in diabetic patients, Circ Cardiovasc. Interv. 4 (2) (2011) 121-129.
34. A.N. Buch, A. Javaid, D.H. Steinberg, et al., Outcomes after sirolimus- And paclitaxeleluting stent implantation in patients with insulin-treated diabetes mellitus, Am. J. Cardiol. 101 (9) (2008) 1253-1258.
35. D.J. Kereiakes, D.E. Cutlip, R.J. Applegate, et al., Outcomes in diabetic and nondiabetic patients treatedwith everolimus- or paclitaxel-eluting stents results fromthe SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system), J. Am. Coll. Cardiol. 56 (25) (2010) 2084-2089.
36. P. Buja, M. Facchin, G. Musumeci, et al., Paclitaxel- And sirolimus-eluting stents in older patientswith diabetesmellitus: results of a real-lifemulticenter registry, Catheter. Cardiovasc. Interv. 81 (7) (2013) 1117-1124.
37. Y. Cho, H.M. Yang, K.W. Park, W.Y. Chung, D.J. Choi, W.W. Seo, K.T. Jeong, S.C. Chae, M.Y. Lee, S.H. Hur, J.K. Chae, I.W. Seong, J.H. Yoon, S.K. Oh, D.I. Kim, K.S. Park, S.W. Rha, Y.S. Jang, J.H. Bae, T.J. Hong, M.C. Cho, Y.J. Kim, M.H. Jeong, M.J. Kim, S.K. Park, I.H. Chae, H.S. Kim, KAMIR Investigators, Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: With analyses for diabetic and nondiabetic subpopulation, JACC Cardiovasc. Interv. 3 (5) (2010) 498-506.
38. W.M. Wolf, H.A. Vlachos, O.C. Marroquin, et al., Paclitaxel-eluting versus sirolimuseluting stents in diabetes mellitus: A report from the NHLBI dynamic registry, Circ Cardiovasc. Interv. 3 (1) (2010) 42-49.
39. S. Desch, D. Schloma, S. Möbius-Winkler, et al., Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: The LIPSIA Yukon trial, JACC Cardiovasc. Interv. 4 (4) (2011) 452-459.
40. J. Daemen, H.M. Garcia-Garcia, N. Kukreja, et al., The long-term value of sirolimusand paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus, Eur. Heart J. 28 (1) (2007) 26-32 (Epub 2006 Nov 29).
41. M. Billinger, J. Beutler, K.R. Taghetchian, et al., Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients, Eur. Heart J. 29 (6) (2008) 718-725.
42. K. Park, K.W. Park, S.W. Rha, et al., Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort, Circ. Cardiovasc. Interv. 5 (2) (2012) 174-184.
43. M. Mayor, A.Z. Malik, R.J. Minor Jr., et al., One-year outcomes from the TAXUS expreß stent versus Cypher stent, Am. J. Cardiol. 103 (7) (2009) 930-936.
44. M. Chiu, D.T. Ko, P.C. Austin, et al., Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients, Circ. Cardiovasc. Qual. Outcomes 2 (2) (2009) 96-107.
45. A. Laynez, G. Sardi, C. Hauville, et al., Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population, Catheter. Cardiovasc. Interv. 81 (5) (Apr 2013) 759-765.
46. P.K. Kuchulakanti, W.W. Chu, R. Torguson, et al., Sirolimus-eluting stents versus paclitaxel-elutin43g stents in the treatment of coronary artery disease in patients with diabetes mellitus, Am. J. Cardiol. 98 (2) (Jul 15 2006) 187-192.
47. K.E. Kip, D.P. Faxon, K.M. Detre, et al., Coronary angioplasty in diabetic patients. the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty registry, Circulation 94 (1996) 1818-1825.
48. R. Kornowski, G.S. Mintz, K.M. Kent, et al., Increase restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular study, Circulation 95 (1997) 1366-1369.
49. M. Sabate, P. Jimenez-Quevedo, D.J. Angiolillo, et al., Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial, Circulation 112 (2005) 2175-2183.
50. C.W. Lee, D.W. Park, B.K. Lee, et al., Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries, Am. J. Cardiol. 97 (2006) 506-511.
51. R. Weßely, A. Kastrati, A. Schömig, Late restenosis in patients receiving a polymercoated sirolimus-eluting stent, Ann. Intern. Med. 143 (2005) 392-394.
52. W. Schuler, R. Sedrani, S. Cottens, et al., SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo, Transplantation 64 (1997) 36-42.
53. S.O. Marx, A.R. Marks, Bench to bedside: The development of rapamycin and its application to stent restenosis, Circulation 104 (2001) 852-855.